Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
Main Authors: | Lixin Du, Jiao Qin, Dengchuan Wang, Yunhui Zhao, Ning Xu, Chaowen Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.987025/full |
Similar Items
-
Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
by: Lixin Du, et al.
Published: (2022-11-01) -
GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway
by: Alessio Mazzieri, et al.
Published: (2023-11-01) -
Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
by: Katarzyna Wołos-Kłosowicz, et al.
Published: (2022-10-01) -
Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
by: Apurva Khedagi, et al.
Published: (2023-03-01) -
SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
by: Bartosz Rolek, et al.
Published: (2023-07-01)